Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays

被引:158
作者
Riendeau, D [1 ]
Charleson, S [1 ]
Cromlish, W [1 ]
Mancini, JA [1 ]
Wong, E [1 ]
Guay, J [1 ]
机构
[1] MERCK FROSST CTR THERAPEUT RES,KIRKLAND,QC H9H 3L1,CANADA
关键词
cyclooxygenase; prostaglandin synthase; nonsteroidal anti-inflammatory drugs; COX-2; inhibitors; platelets; gastrointestinal toxicity;
D O I
10.1139/cjpp-75-9-1088
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Two forms of cyclooxygenase (COX) activity are involved in the synthesis of prostaglandins, prostacyclins, and thromboxanes in mammalian cells. There is now convincing evidence, obtained with a number of structurally distinct inhibitors, that selective COX-2 inhibitors possess anti-inflammatory effects with an improved gastrointestinal tolerability compared with conventional nonsteroidal anti-inflammatory drugs (NSAIDs) affecting both COX-1 and COX-2. As more selective COX-2 inhibitors are being developed, assays with a high degree of sensitivity to inhibition are needed to compare the relative effects of compounds on COX-1 activity. In the present report, we describe a sensitive assay for the inhibition of human COX-1 based on the production of prostaglandin E-2 by microsomes from U937 cells incubated with a subsaturating concentration of arachidonic acid. More than 45 NSAIDs and selective COX-2 inhibitors were tested in this assay. IC50 values ranged from 1 nM for flunixin and flurbiprofen to about 200-500 mu M for salicylate and acetaminophen. Potent and nonselective NSAIDs such as sulindac sulfide, diclofenac, and indomethacin showed IC50 values of <20 nM. Among the compounds that have been reported to show selectivity for COX-2, the rank order of potency against COX-1 was DuP 697 > SC-58451 > celecoxib > nimesulide similar to meloxicam similar to piroxicam similar to NS-398 similar to RS-57067 > SC-57666 > SC-58125 > flosulide > etodolac > L-745,337 > DFU similar to T-614, with IC50 values ranging from 7 nM to 17 mu M. A good correlation was obtained between the IC50 values for the inhibition of microsomal COX-1 and both the inhibition of TXB2 production by Ca2+ ionophore challenged platelets and the inhibition of prostaglandin E-2 production by CHO cells stably expressing human COX-1. However, the microsomal assay was more sensitive to inhibition than cell-based assays and allowed the detection of inhibitory effects on COX-1 for all NSAIDs and selective COX-2 inhibitors examined with discrimination of their potency under conditions of limited availability of arachidonic acid.
引用
收藏
页码:1088 / 1095
页数:8
相关论文
共 54 条
[1]   GASTROINTESTINAL DAMAGE ASSOCIATED WITH THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS [J].
ALLISON, MC ;
HOWATSON, AG ;
TORRANCE, CJ ;
LEE, FD ;
RUSSELL, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (11) :749-754
[2]  
[Anonymous], DRUGS NEWS PERSPECT
[3]   Tumor necrosis factor mediation of NSAID-induced gastric damage: Role of leukocyte adherence [J].
Appleyard, CB ;
McCafferty, DM ;
Tigley, AW ;
Swain, MG ;
Wallace, JL .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1996, 270 (01) :G42-G48
[4]  
ARGENTIERI DC, 1994, J PHARMACOL EXP THER, V271, P1399
[5]   Cyclooxygenase-2 and its regulation in inflammation [J].
Bakhle, YS ;
Botting, RM .
MEDIATORS OF INFLAMMATION, 1996, 5 (05) :305-323
[6]  
BARNETT JW, 1996, Patent No. 0714895
[7]   NSAIDS, COX-2 INHIBITORS, AND THE GUT [J].
BENNETT, A ;
TAVARES, IA .
LANCET, 1995, 346 (8982) :1105-1105
[8]  
BLOWER RP, 1992, J RHEUMATOL S36, V19, P13
[9]   STIMULATION AND INHIBITION OF PROSTACYCLIN FORMATION IN THE GASTRIC-MUCOSA AND ILEUM INVITRO BY ANTI-INFLAMMATORY AGENTS [J].
BOUGHTONSMITH, NK ;
WHITTLE, BJR .
BRITISH JOURNAL OF PHARMACOLOGY, 1983, 78 (01) :173-180
[10]   NSAID-induced gastrointestinal damage - Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus [J].
Champion, GD ;
Feng, PH ;
Azuma, T ;
Caughey, DE ;
Chan, KH ;
Kashiwazaki, S ;
Liu, HC ;
Nasution, AR ;
Nobunaga, M ;
Prichanond, S ;
Torralba, TP ;
Udom, V ;
Utis, D ;
Wang, SR ;
Wong, WS ;
Yang, DJ ;
Yoo, MC .
DRUGS, 1997, 53 (01) :6-19